Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07378839 · ClinicalTrials.gov registry record · NA
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
A NA study of Nausea and Pregnancy Emesis, sponsored by University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07378839: Recruiting NA study of Nausea and Pregnancy Emesis, sponsored by University of Minnesota.
NCT07378839 is a NA study of Nausea and Pregnancy Emesis that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 100 participants, below the 238-participant average among 17 other Nausea trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07378839, a NA study of Nausea and Pregnancy Emesis, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.
Primary Outcome
Measured by the change in the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score, where scores range from 3-15, and a higher score indicates greater severity of nausea and vomiting.
Conditions Studied
Interventions
- BEHAVIORAL Alternate Nostril Breathing
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What NCT07378839 shows while recruiting
NCT07378839 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 238-participant average among 17 other Nausea trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 1 intervention - of which Alternate Nostril Breathing is the first listed.
NCT07378839 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07378839 about?
NCT07378839 is a clinical study titled "Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting". This is a prospective, two-arm, non-blinded randomized controlled study designed to evaluate the effects of a one-week alternate nostril breathing (ANB) intervention on nausea and vomiting severity in pregnant individuals during their first trimester.
What is the current status of trial NCT07378839?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-02-10. Estimated completion is 2027-03-31.
What conditions does trial NCT07378839 study?
This clinical trial studies the following conditions: Nausea, Pregnancy Emesis.
What interventions are being tested in trial NCT07378839?
The interventions under investigation include: Alternate Nostril Breathing (BEHAVIORAL).
Who is sponsoring clinical trial NCT07378839?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07378839 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07378839's enrollment target sits among peer trials
100 10th of 17 higher than 7 of 17 other Nausea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
RECRUITING · NA
-
Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment
RECRUITING · NA
-
Acupressure Wristbands for GLP-1RA Related Nausea
ACTIVE NOT RECRUITING · NA
-
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
COMPLETED · NA
-
Virtual Reality at End-of-life
COMPLETED · NA
-
Inhaled Isopropyl Alcohol for Treatment of Nausea
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI